Charles River Laboratories EBITDA Margin 2010-2025 | CRL

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Charles River Laboratories (CRL) over the last 10 years. The current EBITDA margin for Charles River Laboratories as of March 31, 2025 is .
Charles River Laboratories EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2025-03-31 $4.02B $0.79B 19.59%
2024-12-31 $4.05B $0.80B 19.85%
2024-09-30 $4.06B $0.87B 21.37%
2024-06-30 $4.08B $0.89B 21.87%
2024-03-31 $4.11B $0.90B 21.81%
2023-12-31 $4.13B $0.93B 22.55%
2023-09-30 $4.22B $0.96B 22.75%
2023-06-30 $4.18B $0.96B 22.86%
2023-03-31 $4.09B $0.98B 23.86%
2022-12-31 $3.98B $0.96B 24.02%
2022-09-30 $3.78B $0.95B 25.23%
2022-06-30 $3.69B $0.95B 25.81%
2022-03-31 $3.63B $0.89B 24.63%
2021-12-31 $3.54B $0.86B 24.15%
2021-09-30 $3.43B $0.81B 23.49%
2021-06-30 $3.27B $0.77B 23.61%
2021-03-31 $3.04B $0.70B 23.04%
2020-12-31 $2.92B $0.67B 22.85%
2020-09-30 $2.82B $0.64B 22.63%
2020-06-30 $2.75B $0.59B 21.54%
2020-03-31 $2.72B $0.59B 21.55%
2019-12-31 $2.62B $0.55B 20.98%
2019-09-30 $2.53B $0.53B 21.04%
2019-06-30 $2.45B $0.52B 21.06%
2019-03-31 $2.38B $0.51B 21.33%
2018-12-31 $2.27B $0.49B 21.76%
2018-09-30 $2.14B $0.45B 20.77%
2018-06-30 $2.02B $0.43B 21.03%
2018-03-31 $1.91B $0.42B 21.94%
2017-12-31 $1.86B $0.42B 22.56%
2017-09-30 $1.85B $0.43B 23.19%
2017-06-30 $1.81B $0.41B 22.84%
2017-03-31 $1.77B $0.39B 22.00%
2016-12-31 $1.68B $0.36B 21.64%
2016-09-30 $1.57B $0.34B 21.35%
2016-06-30 $1.49B $0.32B 21.58%
2016-03-31 $1.40B $0.31B 22.32%
2015-12-31 $1.36B $0.30B 22.16%
2015-09-30 $1.34B $0.29B 21.88%
2015-06-30 $1.32B $0.29B 21.70%
2015-03-31 $1.32B $0.28B 21.38%
2014-12-31 $1.30B $0.28B 21.26%
2014-09-30 $1.26B $0.26B 20.92%
2014-06-30 $1.22B $0.26B 21.13%
2014-03-31 $1.17B $0.25B 21.31%
2013-12-31 $1.17B $0.26B 22.06%
2013-09-30 $1.16B $0.26B 22.75%
2013-06-30 $1.14B $0.26B 22.57%
2013-03-31 $1.14B $0.26B 23.26%
2012-12-31 $1.13B $0.27B 23.45%
2012-09-30 $1.14B $0.27B 23.84%
2012-06-30 $1.14B $0.27B 24.04%
2012-03-31 $1.14B $0.28B 24.50%
2011-12-31 $1.14B $0.28B 24.50%
2011-09-30 $1.13B $0.18B 15.96%
2011-06-30 $1.13B $0.16B 13.75%
2011-03-31 $1.13B $0.14B 11.97%
2010-12-31 $1.13B $0.12B 10.67%
2010-09-30 $1.12B $0.22B 19.89%
2010-06-30 $1.14B $0.25B 22.07%
2010-03-31 $1.16B $0.27B 22.91%
2009-12-31 $1.17B $0.27B 23.40%
Sector Industry Market Cap Revenue
Medical Medical Services $7.829B $4.050B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $146.605B 27.50
CVS Health (CVS) United States $81.948B 10.19
Elevance Health (ELV) United States $76.969B 9.93
Cencora (COR) United States $57.219B 19.91
DiDi Global (DIDIY) China $24.191B 25.70
Natera (NTRA) United States $21.906B 0.00
Labcorp Holdings (LH) United States $20.893B 16.95
BioMerieux (BMXMF) France $16.861B 0.00
EUROFINS SCIENT (ERFSF) Luxembourg $13.687B 0.00
CochLear (CHEOY) Australia $12.827B 0.00
Solventum (SOLV) United States $12.768B 13.52
ICON (ICLR) Ireland $12.156B 11.30
Revvity (RVTY) United States $11.964B 20.59
Viatris (VTRS) United States $10.704B 3.68
Medpace Holdings (MEDP) United States $9.298B 24.69
Avantor (AVTR) United States $9.254B 13.45
Sonic Healthcare (SKHHY) Australia $8.886B 0.00
HealthEquity (HQY) United States $8.174B 35.80
Caris Life Sciences,�Inc (CAI) United States $6.744B 0.00
Amplifon S.p.A (AMFPF) Italy $5.378B 29.44
Bausch + Lomb (BLCO) Canada $4.911B 28.92
BrightSpring Health Services (BTSG) United States $3.571B 32.76
Sotera Health (SHC) United States $3.349B 19.03
Surgery Partners (SGRY) United States $2.825B 36.73
Alignment Healthcare (ALHC) United States $2.645B 0.00
Organon (OGN) United States $2.584B 2.75
Concentras Parent (CON) United States $2.551B 14.74
GeneDx Holdings (WGS) United States $2.356B 90.72
Ardent Health (ARDT) United States $2.027B 8.64
Progyny (PGNY) United States $1.990B 43.79
PACS (PACS) United States $1.932B 0.00
Premier (PINC) United States $1.736B 13.18
GoodRx Holdings (GDRX) United States $1.695B 33.89
Teladoc Health (TDOC) United States $1.460B 0.00
Establishment Labs Holdings (ESTA) $1.298B 0.00
Pediatrix Medical (MD) United States $1.127B 8.58
CareDx (CDNA) United States $1.121B 17.50
Ryman Healthcare (RYHTY) New Zealand $0.970B 0.00
Agilon Health (AGL) United States $0.923B 0.00
QDM (QDMI) Hong Kong, SAR China $0.848B 291.00
AMN Healthcare Services Inc (AMN) United States $0.810B 7.58
Nutex Health (NUTX) United States $0.637B 9.64
Embecta (EMBC) United States $0.612B 4.12
InnovAge Holding (INNV) United States $0.559B 0.00
SBC Medicals (SBC) United States $0.523B 0.00
LifeMD (LFMD) United States $0.512B 0.00
Sonida Senior Living (SNDA) United States $0.482B 0.00
Auna S.A (AUNA) Luxembourg $0.471B 10.60
Omada Health (OMDA) $0.455B 0.00
So-Young (SY) China $0.390B 0.00
Enhabit (EHAB) United States $0.357B 29.38
COMPASS Pathways (CMPS) United Kingdom $0.344B 0.00
Performant Healthcare (PHLT) United States $0.321B 0.00
Oncology Institute (TOI) United States $0.279B 0.00
Beauty Health (SKIN) United States $0.241B 0.00
DocGo (DCGO) United States $0.152B 24.83
Pheton Holdings (PTHL) China $0.138B 0.00
Sera Prognostics (SERA) United States $0.107B 0.00
Ascend Wellness Holdings (AAWH) United States $0.079B 0.00
KindlyMD (NAKA) United States $0.074B 0.00
IceCure Medical (ICCM) Israel $0.061B 0.00
NeueHealth (NEUE) United States $0.061B 0.00
ModivCare (MODV) United States $0.046B 0.00
Biodesix (BDSX) United States $0.045B 0.00
Basel Medical Group (BMGL) Singapore $0.042B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.035B 0.00
OSR Holdings (OSRH) United States $0.023B 0.00
Intelligent Bio Solutions (INBS) United States $0.012B 0.00
BioNexus Gene Lab (BGLC) $0.009B 0.00
Co-Diagnostics (CODX) United States $0.008B 0.00
SeaStar Medical Holding (ICU) United States $0.007B 0.00
XWELL (XWEL) United States $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
INVO Fertility (IVF) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.000B 0.00